TuHURA Biosciences (HURA) announced with Kineta (KANT) that TuHURA stockholders approved all of the proposals set forth at the company’s special meeting of stockholders held today, June 23. The proposals included an increase of the company’s authorized shares to 200M shares and a proposal to reincorporate the company in Delaware. Additionally, Kineta stockholders approved the proposed merger with TuHURA at Kineta’s special meeting. The parties anticipate that the merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences initiated with a Buy at Brookline
- TuHURA Biosciences Approves Executive Salary Increases
- TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0
- TuHURA Biosciences Secures $12.6M for Strategic Initiatives
- TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating